Have £2k to spend? 2 FTSE 100 dividend stocks for 2020 I’d buy to retire on

Royston Wild picks out two income heroes he’d stash in his shares portfolio for 2020.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Looking for top dividend stocks to load into your ISA for 2020? GlaxoSmithKline (LSE: GSK) is one I’d happily buy on the strength of its product pipeline, one which promises to deliver supreme profits growth through the 2020s and probably beyond.

The Footsie drug giant has around 40 medicines in the development stage in big growth areas like oncology and HIV, a pipeline that is constantly delivering a steady stream of future revenues drivers. And I reckon the business could prove to be a wise pick for 2020 in particular as a backdrop of intense geopolitical and macroeconomic tetchiness boosts demand for safe-haven sectors like pharmaceuticals.

A mix of this rush-to-safety buying and some strong trading releases, such as third-quarter numbers that showed product sales boomed 16% to £9.4bn, has helped Glaxo’s share price also rise 16% so far in the current year. A low forward P/E ratio of 14.4 times gives plenty of room for more strength in the New Year too.

One final thing: at current prices, Glaxo also boasts a bruising 4.6% dividend yield for 2020, created by City expectations of another 80p per share annual payout. But it’s not the only income hero that I’d buy for the year ahead as I reckon National Grid (LSE: GSK) should also attract no shortage of safe-haven buying.

Supercharge your income flows

With a cooling UK (and global) economy raising the likelihood of a rush of profit warnings next year, firms that supply essential services like water, sewage management, electricity and gas are worth their weight in gold. To illustrate this,  National Grid, which operates the country’s vast network of pylons and substations, has seen its share price jump 17% so far in 2019.

There is some regulatory uncertainty here as Labour threatens to nationalise key utilities, but the likely failure of the party to seize power after tomorrow’s general election means that this only major threat to National Grid’s long-term profitability will be taken off the table.

Illustrating the company’s quality as a solid earnings generator even in tough economic times, City forecasts suggest that the network operator will follow a predicted 33% bottom-line rise in the current fiscal year (to March 2020) with an additional 6% advance in the following period. And as you’d expect, this leads to expectations of further dividend growth too.

Last year’s 47.34p per share total dividend is anticipated to rise to 48.7p in the present period and then to 50.1p in financial 2021, estimates that yield a mighty 5.5% and 5.6% respectively. But this is not the only reason to celebrate National Grid at current prices as it also commands an undemanding forward P/E ratio of 15.1 times, one that fails to fully reflect its supreme defensive qualities and leaves much scope for share price gains in the new calendar year.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Senior couple crossing the road on a city street. They are walking with shopping bags while Christmas shopping.
Investing Articles

9.4% yield! A magnificent dividend stock I’d buy to target a lifelong second income

Royston Wild’s creating a list of the London stock market's best dividend shares. Here's one he's hoping to buy for…

Read more »

Investing Articles

£17,000 in savings? Here’s how I’d target a weighty passive income

Funnelling any spare savings towards building a passive income is certainly a smart idea, but how to find the right…

Read more »

Investing Articles

Why is this FTSE 250 giant up 35% in two weeks?

Seeing a share price soaring can often be a reason to be cautious, but I still think there's a lot…

Read more »

Light bulb with growing tree.
Investing Articles

Is there still time to snap up this ex-penny stock in May?

A penny stock no more but a promising low-cap company nonetheless. Our writer examines the growth prospects of this sustainable…

Read more »

Close-up of British bank notes
Investing Articles

Here’s how I’d target a £1,890 second income by investing £35 a week

Christopher Ruane explains how, for a fiver a day, he'd aim to build a second income of almost £1,900 in…

Read more »

Dividend Shares

£5k in savings? Here’s how I’d try to turn it into £414 of monthly passive income

Jon Smith explains how he'd use both dividend and growth shares to help him take a lump sum of £5k…

Read more »

Fans of Warren Buffett taking his photo
Investing Articles

Warren Buffett’s sitting on $189bn in cash. What’s this telling us?

Legendary stock market investor Warren Buffett's currently sitting on a cash pile bigger than most FTSE 100 companies. Is this…

Read more »

Typical street lined with terraced houses and parked cars
Dividend Shares

Here’s how much income I’d make if I invested all my ISA in Taylor Wimpey shares

Jon Smith explains why researching Taylor Wimpey shares could be a good move, based on historical dividend payments and the…

Read more »